In addition, in Japan, T-DM1 was approved only from August 2020, for the purposes of health insurance coverage, as adjuvant therapy for early-stage HER2-positive breast cancer patients who have not achieved pCR. This evidence concerns the gene ERBB2 and breast cancer.